指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

美国感染病学会2025年复杂性尿路感染管理与治疗指南:复杂性尿路感染抗生素治疗选择

Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections-Selection of Antibiotic Therapy for Complicated Urinary Tract Infections.
指南 / 共识 · Clin Infect Dis · 2026-01-01
一句话结论美国感染病学会指南建议:疑似复杂性尿路感染初始经验性治疗应优先选择推荐抗生素而非替代选项,并按病情严重程度和抗菌药物管理分层。

该指南由美国感染病学会制定,针对疑似复杂性尿路感染的经验性抗生素选择,平衡初始经验性治疗适当性、病情严重程度与抗菌药物管理。推荐基于2008年以来系统文献综述及2000年以来耐药预测因素文献,采用GRADE方法评级证据确定性与推荐强度。指南建议初始经验性治疗优先选择推荐抗生素而非替代选项,按病情严重程度和抗菌药物管理考量分层。选择具体抗生素时建议采用四步流程:评估病情严重程度、考虑患者特异性耐药风险因素优化覆盖、评估其他患者特异性因素减少不良事件、脓毒症患者参考当地药敏谱。最终根据尿培养结果选择针对性窄谱有效治疗。

要点

  • 疑似复杂性尿路感染初始经验性治疗,建议优先选择推荐抗生素而非替代选项(美国感染病学会指南建议)。
  • 选择具体经验性抗生素时建议采用四步流程:先评估病情严重程度以初步优先排序抗生素。
  • 第二步考虑患者特异性耐药尿路病原体风险因素以优化覆盖范围。
  • 第三步评估其他患者特异性因素以减少不良事件风险。
  • 脓毒症患者如当地药敏谱可用,建议查阅以进一步提高适当经验性治疗的可能性。

适用人群与场景

  • 疑似复杂性尿路感染患者,需经验性选择抗生素。
  • 指南强调需平衡适当初始经验性治疗、患者病情严重程度与抗菌药物管理。

处置流程与药物剂量

  • 第一步:评估病情严重程度,用于初步优先排序抗生素选择。
  • 第二步:考虑患者特异性耐药尿路病原体风险因素,用于优化覆盖范围。
  • 第三步:评估其他患者特异性因素,用于减少不良事件风险。
  • 第四步:对脓毒症患者,如当地药敏谱可用,查阅当地药敏谱以进一步提高给予适当经验性治疗的可能性。
  • 初始经验性治疗建议在推荐抗生素中选择而非替代选项,按病情严重程度和抗菌药物管理考量分层。
  • 最终治疗建议根据尿培养结果选择针对性窄谱的有效治疗。

研究设计与关键结果

  • 指南小组基于2008年以来发表的系统文献综述(聚焦获批用于复杂性尿路感染的抗生素类别的比较获益与伤害)及2000年以来耐药预测因素文献制定推荐。
  • 推荐采用GRADE方法评级证据确定性和推荐强度。
  • 指南指出许多获批治疗复杂性尿路感染的抗生素类别在随机对照试验中显示出与其他类别相似的疗效。
  • 细菌耐药流行率始终在变化,并将开发新抗生素。

证据类型、等级与局限

  • 证据类型:指南(美国感染病学会)。
  • 证据分级体系:GRADE方法。
  • 推荐强度:指南小组建议(suggests)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该指南建议临床医生在床旁选择复杂性尿路感染经验性抗生素时,优先从推荐抗生素中选择而非替代选项,并按病情严重程度和抗菌药物管理分层。
  • 指南建议采用四步流程个体化选择抗生素:评估病情严重程度、考虑耐药风险因素、评估其他患者特异性因素、脓毒症患者查阅当地药敏谱。
  • 指南建议最终根据尿培养结果选择针对性窄谱治疗。

指南或共识出处

  • 美国感染病学会2025年复杂性尿路感染管理与治疗指南:复杂性尿路感染抗生素治疗选择(Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections-Selection of Antibiotic Therapy for Complicated Urinary Tract Infections)
  • 制定机构:美国感染病学会
  • 年份:2025年

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: These recommendations address the empiric choice of antibiotics in suspected complicated urinary tract infection (cUTI). Issues to balance include the need for appropriate initial empiric antimicrobial therapy, the patient's severity of illness, and antimicrobial stewardship concerns.

METHODS: The panel's recommendations are based upon evidence derived from systematic literature reviews that focused on comparative benefits and harms of classes of antibiotics approved for cUTI, starting with publications from 2008 onwards, and our review of predictors of resistance in uropathogens included references identified since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

RESULTS: The guidelines panel suggests initially selecting among preferred empiric antibiotic choices rather than alternative options, stratified for the patient's severity of illness and antimicrobial stewardship considerations. When choosing among these antibiotics for a specific patient, the guideline panel suggests a 4-step process to account for changing resistance patterns and individualized patient needs. The steps are: (1) assess the severity of illness (for initial prioritization of antibiotics), (2) consider patient-specific risk factors for resistant uropathogens (for optimization of coverage), (3) evaluate other patient-specific considerations (to reduce the risk of adverse events), and (4) for patients with sepsis, consult a relevant local antibiogram if available (to further improve the likelihood of giving appropriate empiric therapy). Lastly, the guideline panel suggests selecting definitive effective therapy with a targeted spectrum based on the result of the urine culture.

CONCLUSIONS: Many of the classes of antibiotics approved to treat cUTI demonstrate similar efficacy as other classes of antibiotics in randomized controlled trials. Bacterial resistance prevalence is always changing, and new antibiotics will be developed. In this context, the guidelines panel provides recommendations for choosing empiric antibiotic therapy for cUTI that will help clinicians decide among available antibiotic options at the point of care.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

参考来源

  1. Trautner BW, Cortés-Penfield NW, Gupta K, et al. Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections-Selection of Antibiotic Therapy for Complicated Urinary Tract Infections. Clin Infect Dis. 2026. PMID: 41419213. doi:10.1093/cid/ciaf460

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。